This latest interview is excellent and David provides a clear explanation of the advantages we gained with Fast Track approval. It can't be easy to face delicate political questions about Biotechs working with the new FDA in a public forum; yet David is as reassuring about ATH's position as he is candid and honest. For all the political uncertainties that abound right now, David has steered us into a great position to get this seriously moving.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.001(6.67%) |
Mkt cap ! $147.3M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.7¢ | 1.5¢ | $770.2K | 49.71M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 2038332 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 349000 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |